Focused On-demand Library for RNA-binding motif protein, X chromosome

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P38159

UPID:

RBMX_HUMAN

Alternative names:

Glycoprotein p43; Heterogeneous nuclear ribonucleoprotein G

Alternative UPACC:

P38159; B4E3U4; D3DWH0; E9PG86; Q5JQ67; Q8N8Y7; Q969R3

Background:

RNA-binding motif protein, X chromosome, known as Glycoprotein p43 or Heterogeneous nuclear ribonucleoprotein G, plays a pivotal role in pre- and post-transcriptional processes. It regulates gene transcription, alternative splicing, and is part of the supraspliceosome complex influencing mRNA splice site selection. This protein is also involved in tumor suppression and cytoplasmic TNFR1 trafficking pathways.

Therapeutic significance:

Linked to Intellectual developmental disorder, X-linked, syndromic 11, characterized by moderate intellectual disability and craniofacial dysmorphism, understanding the role of RNA-binding motif protein, X chromosome could open doors to potential therapeutic strategies.